Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1.

Articolo

Data di Pubblicazione:

2013

Tipologia CRIS:

03C-Nota a Sentenza

Keywords:

Antiviral Agents; therapeutic use, Genotype, Hepacivirus; genetics, Hepatitis C; drug therapy, Humans, Oligopeptides; therapeuti/c use, Proline; analogs /&/ derivatives

Elenco autori:

Calcagno A;Boglione L;De Rosa FG;Di Perri G;Bonora S

Autori di Ateneo:

BONORA Stefano

CALCAGNO Andrea

DE ROSA Francesco Giuseppe

DI PERRI Giovanni

Link alla scheda completa:

https://iris.unito.it/handle/2318/141411

Link al Full Text:

https://iris.unito.it/retrieve/handle/2318/141411/23233/CID-S-12-04310%20copia%20(1).pdf

Pubblicato in:

CLINICAL INFECTIOUS DISEASES

Journal

Dati Generali

URL

http://dx.doi.org/10.1093/cid/cit087

Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1.

Calcagno A;Boglione L;De Rosa FG;Di Perri G;Bonora S

CLINICAL INFECTIOUS DISEASES

Dati Generali

URL